20.500.12556/DiRROS-15616 Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma a comparative retrospective study from the InspECT and Slovenian Cancer Registry Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC%IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation. electrochemotherapy metastatic melanoma skin metastases elektrokemoterapija metastatski melanom kožne metastaze true false true MDPI Angleški jezik Slovenski jezik by Authors Neznano 2022-10-08 03:34:48 2022-10-10 13:23:29 2022-10-11 03:35:07 0000-00-00 00:00:00 2021 0 0 Nasl. z nasl. zaslona; Opis vira z dne 31. 8. 2021; str. 4289-1-4289-13 no. 17 Vol. 13 2021 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 2021-08-25 616.5 2072-6694 10.3390/cancers13174289 74755075 https://www.mdpi.com/2072-6694/13/17/4289 1 a2c25649-4698-11ed-bea5-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=20656 RAZ_Campana_Luca_Giovanni_2021.pdf RAZ_Campana_Luca_Giovanni_2021.pdf 1 F2DD7681624B085555665A4B6B6F5059 53f29cc11df6c9396856cc1ab51d431a9a414d6665e21c76d4a25544cf211ab4 63d83e9c-487d-11ed-bea5-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=20659 Onkološki inštitut Ljubljana 0 0 0